Cancer clinical trials in the region Nouvelle-Aquitaine

454 currently recruiting clinical trials
Region Nouvelle-Aquitaine
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required histologic types
Acute lymphoblastic leukemia (ALL) Other acute leukemia
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
Other mutation KMT2A NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Acute leukemia #NCT04065399 #2020-004104-34
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome Acute leukemia #NCT04707300 #2019-004883-23
Required histologic types
CLL (Chronic Lymphocytic Leukemia) Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML)
4 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT07232602 #2025-522253-19-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Prostate cancer #NCT07258407 #2025-523273-41-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
T.O.A.D. Oncology SA
Phase 1 / Phase 2 Lung cancer Prostate cancer Stomach and esophageal cancer #NCT05434234
Required histologic types
SCLC (Small Cell Lung Cancer) NSCLC (Non-Small Cell Lung Cancer) Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06265727
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Corbus Pharmaceuticals Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05410145 #2023-508517-16-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
D3 Bio (Wuxi) Co., Ltd